Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
| ▸ | MYC | P01106 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | AHR | P35869 | 1/20 | 0.38 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.37 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19979961 | 0.86 | MYC (0.53) | CYP2A6KDM4EALDH1A1MYCRAB9A | |
| SCHEMBL19979962 | 0.81 | CYP1A2 (0.46) | KDM4EMAPK10 | |
| SCHEMBL945426 | 0.79 | CYP2A6 (0.41) | PARP1CYP2A6KDM4EALDH1A1MYC | |
| SCHEMBL29551168 | 0.78 | CAPN1 (0.55) | PARP1KDM4EMYCCAPN1NAPRT | |
| SCHEMBL5663804 | 0.78 | CAPN1 (0.55) | PARP1KDM4EMYCCAPN1NAPRT | |
| SCHEMBL299870 | 0.78 | HCRTR1 (0.48) | PARP1CYP2A6KDM4EALDH1A1HPGD | |
| SCHEMBL30597933 | 0.77 | MEN1 (0.56) | KDM4EALDH1A1RAB9ACAPN1 | |
| SCHEMBL28309777 | 0.76 | ADORA3 (0.34) | CYP2A6KDM4EALDH1A1SYKMAPT | |
| SCHEMBL15758137 | 0.76 | PARP1 (0.44) | PARP1KDM4EALDH1A1RAB9AMAPT | |
| SCHEMBL9826144 | 0.76 | CYP2A6 (0.47) | CYP2A6KDM4EALDH1A1MAPK10SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2200440-A1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | Crestone, Inc. (US) | 2010-06-30 | — | — | EP | claimed |
| WO-2009015208-A1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | REPLIDYNE, INC. (US) | 2009-01-29 | — | — | WO | claimed |
| US-11851428-B2 | Activator of TREK (TWIK RElated K+channels) channels | ONO PHARMACEUTICAL CO., LTD. (JP) | 2023-12-26 | — | — | US | disclosed |
| US-20210347773-A1 | ACTIVATOR OF TREK (TWIK RELATED K+ CHANNELS) CHANNELS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-11-11 | — | — | US | disclosed |
| US-11046683-B2 | Activator of TREK (TWIK RElated K+ channels) channels | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-06-29 | — | — | US | disclosed |
| US-20190322662-A1 | ACTIVATOR OF TREK (TWIK RELATED K+ CHANNELS) CHANNELS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-10-24 | — | — | US | disclosed |
| EP-2200440-A1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | Crestone, Inc. (US) | 2010-06-30 | — | — | EP | disclosed |
| WO-2009015208-A1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | REPLIDYNE, INC. (US) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11851428-B2 | Activator of TREK (TWIK RElated K+channels) channels | KCNJ11, KCNJ1, KCNJ8 | PARP1 2920/4885CYP2A6 3644/4885KDM4E 3251/4885 |
| US-20190322662-A1 | ACTIVATOR OF TREK (TWIK RELATED K+ CHANNELS) CHANNELS | KCNJ11, KCNJ1, KCNJ8 | PARP1 2920/4885CYP2A6 3644/4885KDM4E 3251/4885 |
| US-11046683-B2 | Activator of TREK (TWIK RElated K+ channels) channels | KCNJ11, KCNJ1, KCNJ8 | PARP1 2920/4885CYP2A6 3644/4885KDM4E 3251/4885 |
| US-20210347773-A1 | ACTIVATOR OF TREK (TWIK RELATED K+ CHANNELS) CHANNELS | KCNJ11, KCNJ1, KCNJ8 | PARP1 2920/4885CYP2A6 3644/4885KDM4E 3251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.